Summit Therapeutics PLC (NASDAQ:SMMT) Stock Has Consensus Price Target of $25.91

Posted by Geri Gentry on Sep 27th, 2026

Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) has earned an average rating of “Hold” from the seventeen research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $25.91.

Several research firms have recently commented on SMMT. Guggenheim reaffirmed a “buy” rating on shares of Summit Therapeutics in a report on Wednesday, August 26th. Leerink Partners upgraded shares of Summit Therapeutics from an “underperform” rating to a “market perform” rating and increased their price objective for the stock from $12.00 to $13.00 in a research note on Wednesday, August 12th. KeyCorp reissued an “overweight” rating on shares of Summit Therapeutics in a report on Monday, June 1st. Summit Redstone set a $25.00 target price on Summit Therapeutics in a research note on Wednesday, September 9th. Finally, HC Wainwright restated a “neutral” rating on shares of Summit Therapeutics in a research note on Wednesday.

Read Our Latest Report on SMMT

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SMMT. Tidal Investments LLC increased its position in Summit Therapeutics by 0.7% in the second quarter. Tidal Investments LLC now owns 121,097 shares of the company’s stock worth $1,764,000 after buying an additional 783 shares during the period. Engineers Gate Manager LP acquired a new position in shares of Summit Therapeutics during the second quarter valued at $989,000. Nykredit A S acquired a new position in shares of Summit Therapeutics during the second quarter valued at $111,000. AXQ Capital LP grew its position in shares of Summit Therapeutics by 98.1% during the second quarter. AXQ Capital LP now owns 93,624 shares of the company’s stock worth $1,364,000 after acquiring an additional 46,356 shares during the last quarter. Finally, Two Sigma Securities LLC bought a new position in shares of Summit Therapeutics during the second quarter worth about $182,000. Institutional investors and hedge funds own 4.61% of the company’s stock.

Summit Therapeutics Price Performance

Shares of SMMT opened at $15.61 on Tuesday. The stock has a market capitalization of $12.45 billion, a PE ratio of -13.94 and a beta of -1.24. The business’s fifty day moving average price is $14.89 and its 200 day moving average price is $16.33. Summit Therapeutics has a 12-month low of $12.07 and a 12-month high of $29.23.

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last released its earnings results on Thursday, July 23rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01). As a group, research analysts anticipate that Summit Therapeutics will post -1.2 earnings per share for the current fiscal year.

Summit Therapeutics Company Profile

(Get Free Report)

Summit Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of cancer. The company’s lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition against PD-1 with selective inhibition of vascular endothelial growth factor A (VEGF-A). Summit is evaluating ivonescimab in clinical studies involving patients with non-small cell lung cancer and other solid tumors.

Summit has entered into a licensing and collaboration agreement with Akeso, a biotechnology company that discovered and developed ivonescimab.